Carna Biosciences Signs Reagent Supply Agreement With Caliper Life Sciences

< BACK TO SCIENTIFIC starstarstarstarstar   Science - Scientific Press Release
8th August 2008, 07:17pm - Views: 660





Science Science Carna Biosciences, Inc. 1 image






Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences


KOBE, Aug. 8/Kyodo JBN- AsiaNet/--


Carna Biosciences, Inc. ("Carna") is pleased to announce the signing of a collaborative agreement with

Caliper Life Sciences, Inc. USA ("Caliper") on August 6 (US Eastern Daylight Time). Carna will supply a

set of discrete protein kinases aiding the expansion of Caliper's kinase profiling and assay development

services, and ProfilerPro Kinase Selectivity Assay Kits. Caliper's products and services are widely used

and highly regarded by leading pharmaceutical and biotech companies. The selection of Carna as a

Preferred Provider enhances the visibility and use of Carna's products in the area of kinase inhibitor drug

discovery - a major focus of targeted therapy in the areas of cancer, neurological, and autoimmune

diseases.


"I am proud of the expression and purification technologies that Carna has developed in order to produce

nearly 300 human kinases to date, and even more pleased that Caliper has selected Carna Biosciences

as a principle supplier for Caliper's ProfilerPro Kits," said Kohichiro Yoshino, President and CEO of Carna

Biosciences. "Caliper is an established and reliable partner to the pharmaceutical and biotech industry.


Working with Caliper provides Carna with access to a wealth of new opportunities to expand sales of

protein kinases throughout the worldwide market. This synergistic impact of combining Caliper's advanced

instrumentation with the wide selection and premier quality reagents provided by Carna will greatly benefit

both companies and their clients. We anticipate that this expanded relationship with Caliper will further

position us to explore R&D Partnerships with global biopharmaceutical companies.


About Carna Biosciences, Inc. 

Carna Biosciences, Inc. (www.carnabio.com), founded in April 2003, is a Japanese biotechnology

company conducting intercellular signaling-based drug discovery programs, as well as providing drug

discovery services to pharmaceutical companies, using proprietary technologies in gene cloning, active

kinase protein expression, protein purification and homogeneous assay development.


The company provides products and services including protein kinases, profiling and screening services,

assay development services and crystallography products and services.


About Caliper Life Sciences, Inc. 

Caliper Life Sciences, Inc. (www.caliperls.com) is a premier provider of cutting-edge technologies enabling

researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests

more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between

in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's

portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical

imaging technologies, and discovery & development outsourcing solutions.


Source: Carna Biosciences, Inc.


  Contact:

  Tomohisa Yamazaki, 

  Manager

  Corporate Planning

  Carna Biosciences, Inc.

  Phone: +81-78-302-7039

  Fax: +81-78-302-6665

  E-mail: ir-team@carnabio.com

  URL: http://www.carnabio.com





To view this and other AsiaNet releases please visit http://www.asianetnews.net








news articles logo NEWS ARTICLES
Contact News Articles |Remove this article